Tier 2 — strong

Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials

Jimmy Wen, Burhaan Syed, Solomon Kim, Mouhamad Shehabat, Ubaid Ansari, Daniel I Razick, Muzammil Akhtar, David Pai
Cureus 2024 16(8):e65961

Bibliography

PubMed
PMID 39221308
PubMed Central
PMC11365583
DOI
10.7759/cureus.65961
Funding
The authors declared that no financial support was received from any organization for the submitted work.
Competing interests
The authors declared no relevant financial relationships or other relationships that could appear to have influenced the work.

Study snapshot

DesignPRISMA-guided systematic review of randomized controlled trials identified across four databases.
ModelAdults in randomized NMN supplementation trials; mean age 58.0 years across the included studies.
Sample10 studies; 437 participants.
InterventionOral NMN 150–1200 mg/day across included trials.
DurationMean follow-up 9.6 weeks; range 4–12 weeks.
EndpointsGrip strength; Skeletal mass index; Physical performance; Aerobic performance; Body composition; Adverse events

What the study showed, in plain terms

This 2024 systematic review examined 10 randomized NMN trials involving 437 participants, focusing on physical performance and tolerability.

Physical-performance measures showed non-significant improvement overall, while body composition and muscle mass were not meaningfully changed. No serious adverse effects attributed to NMN were identified in the reviewed trials.

Because the studies were few, short and heterogeneous, the review does not establish that NMN improves strength or exercise performance.

Key findings

  • 10 studies with 437 participants were included; mean age was 58 years.
  • NMN doses ranged from 150 to 1200 mg/day; follow-up ranged from 4 to 12 weeks.
  • Physical strength and aerobic-performance parameters improved non-significantly overall.
  • Body composition and muscle mass were not significantly affected.
  • No serious adverse effects attributed to NMN were reported in the included studies.

What this study can and cannot tell us

The review did not provide a formal pooled meta-analysis of the main physical-performance outcomes and included heterogeneous trials with different populations, doses and outcome definitions.

The small number of studies and short follow-up prevent firm conclusions about efficacy or uncommon/long-term adverse effects.

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology